Preoperative ultrasound-guided injection of nanocarbon for central lymph node dissection in patients with papillary thyroid carcinoma Authors: Ying Wang, Yan Si, Jing Wu, Hui Lu, Jifu Wei, Qiang Ding Published: 2024 ABSTRACT To explore better methods for tracing central lymph nodes in patients with papillary thyroid carcinoma by comparing the differences in the numbers and staining rates of central lymph nodes as well as the degree of nanocarbon extravasation between the preoperative ultrasound-guided injection of nanocarbon particles and the intraoperative injection of nanocarbon particles. A total of 302 patients were randomly divided into a preoperative ultrasound-guided injection group and an intraoperative injection group. The number and degree of staining of the lymph nodes in each subgroup of central lymph nodes, including linea alba cervical lymph nodes, Delphian lymph nodes, and pretracheal and paratracheal lymph nodes, were recorded and analyzed. The extent of dye extravasation was reduced when nanocarbon was injected preoperatively. Significantly more linea alba cervical lymph nodes and pretracheal and paratracheal lymph nodes were detected in the preoperative injection group. Preoperative injection of nanocarbon can accelerate the staining and detection of central lymph nodes in patients with Hashimoto’s thyroiditis, clinically positive lymph nodes (cN1) and tumors with diameters > 1 cm. Preoperative ultrasound-guided injection of nanocarbon can reduce the likelihood of dye spillage and improve the staining rate as well as the detection rate of central lymph nodes. Introduction Thyroid cancer is the diagnosis for 586,000 people worldwide, ranking 9th in incidence in 20201. The most prevalent type of thyroid cancer is papillary thyroid carcinoma (PTC), which accounts for approximately 90% of all thyroid cancer cases2. PTC predisposes patients to early central lymph node metastases. The rate of central lymphatic metastasis is reportedly 20–90%3, and it is a significant and independent predictor of outcomes4. Usually, central lymph nodes are divided into 3 subgroups according to their location: linea alba cervical lymph nodes, which are located underneath the conjugation line of the bilateral sternohyoideus muscles; Delphian lymph nodes (also called prelaryngeal lymph nodes), which are located above the cricothyroid membrane and cricoid cartilage; and pretracheal and paratracheal lymph nodes, which are located in front of and beside the trachea. Moreover, reoperation after the recurrence of central lymph node metastases may induce various complications, such as permanent hypoparathyroidism, chyle leakage, and injury to adjacent organs5. Therefore, extensive central lymph node dissection is important in the surgical treatment of PTC. In recent decades, nanocarbon has been widely used as a lymphatic tracer in the surgical treatment of PTC6. During surgery, a nanocarbon solution with suspended granules is injected into the thyroid gland. The nanocarbon granules penetrate capillary lymphatic vessels and drain into the lymph nodes, staining them black and thereby aiding surgeons in the identification and removal of the lymph nodes. However, in clinical practice, some small or obscured central nodes remain unstained, making them easy to miss and potential sites of recurrence. In addition, injury to thyroid membranes during surgery can lead to extravasation of nanocarbon particles, which stains the surgical field and thus affects the postprocedure period. Preoperative injection of nanocarbon can improve the degree of staining and the completeness of central lymph node dissection7,8. However, no related studies have evaluated the effect of the preoperative injection of nanocarbon on the extent of dissection of each subgroup of central lymph nodes in patients with different thyroid conditions. Moreover, there is a lack of standard procedures. In this study, we injected nanocarbon either preoperatively under ultrasound guidance or intraoperatively and compared the numbers of dissected central lymph nodes, the staining rates of central lymph nodes, the detection rates of central lymph nodes, and the nanocarbon extravasation rates to explore better tracing methods. Results Baseline characteristics A total of 302 patients were recruited and randomly divided into two groups, the POI group (150 patients) and the IOI group (152 patients). There was no significant difference in the sex distribution, age distribution, tumor size, prevalence of Hashimoto’s thyroiditis, or results of the preoperative assessment of central lymph nodes between the POI group and the IOI group (Table 1).Table 1Clinical features of patients in the POI and the IOI groups.VariablesPOI groupIOI groupPGender (male/ female)35/11539/1130.474Age (mean ± standard deviation)44.49 ± 11.6043.22 ± 11.560.342Hashimoto’s thyroiditis33/15030/1520.628Abnormal central lymph nodes38/15030/1520.307Tumor diameter > 1 cm52/15043/1520.233 Table 1Clinical features of patients in the POI and the IOI groups.VariablesPOI groupIOI groupPGender (male/ female)35/11539/1130.474Age (mean ± standard deviation)44.49 ± 11.6043.22 ± 11.560.342Hashimoto’s thyroiditis33/15030/1520.628Abnormal central lymph nodes38/15030/1520.307Tumor diameter > 1 cm52/15043/1520.233 Clinical features of patients in the POI and the IOI groups. Surgical parameters All the enrolled patients underwent total thyroidectomy or lobectomy followed by unilateral central lymph node dissection. A hematoma between the thyroid and sternothyroid muscles developed in 5 patients in the POI group. The skin at the puncture site was discolored in 1 patient in the early stage of the trial, and no leakage occurred when we retained 0.2 ml of air to sweep away the residual nanocarbon in the needle. Nanocarbon spilled in 33 patients in the IOI group and 0 patients in the POI group during thyroid lobectomy. Numbers and detection rates of central lymph nodes Central lymph nodes were undyed in 16.3% of patients in the POI group and in 26.9% of patients in the IOI group. Neither the detection rates nor the numbers of Delphian lymph nodes were significantly different between the POI and IOI groups. A total of 66 linea alba cervical lymph nodes were detected in 47 patients in the POI group. In the IOI group, 22 linea alba cervical lymph nodes were detected in 20 patients. The number and the detection rate were higher in the POI group than in the IOI group. Pretracheal and paratracheal lymph nodes were detected in all the enrolled patients, but more of these nodes were detected in the POI group than in the IOI group (Table 2).Table 2Comparison of detection rates and numbers of central lymph nodes between the POI and the IOI groups.Subgroups of central lymph nodesPOI groupIOI group95% CIPDelphian lymph nodes61.3%57.2% − 0.89–1.940.4690.95 ± 0.871 (0, 1)0.00–0.000.282Linea alba cervical lymph nodes31.3%13.2%9.09–19.880.0001 (0, 1)0 (0, 1)0.00–0.000.000Pretracheal and paratracheal lymph nodes8.42 ± 2.437.68 ± 3.070.12–1.370.020 Table 2Comparison of detection rates and numbers of central lymph nodes between the POI and the IOI groups.Subgroups of central lymph nodesPOI groupIOI group95% CIPDelphian lymph nodes61.3%57.2% − 0.89–1.940.4690.95 ± 0.871 (0, 1)0.00–0.000.282Linea alba cervical lymph nodes31.3%13.2%9.09–19.880.0001 (0, 1)0 (0, 1)0.00–0.000.000Pretracheal and paratracheal lymph nodes8.42 ± 2.437.68 ± 3.070.12–1.370.020 Comparison of detection rates and numbers of central lymph nodes between the POI and the IOI groups. The number of central lymph nodes was further analyzed in patients with Hashimoto’s thyroiditis, in cN1 patients, and in patients with tumors measuring > 1 cm in diameter. In patients with Hashimoto’s thyroiditis, suspicious central lymph nodes, or tumors measuring > 1 cm in diameter, the number of Delphian lymph nodes was not significantly different between the POI and IOI groups. In patients with Hashimoto’s thyroiditis, abnormal central lymph nodes, and tumors measuring > 1 cm in diameter, the number of linea alba cervical lymph nodes was significantly greater in the POI group. In the POI group, the number of pretracheal and paratracheal lymph nodes was greater in patients with abnormal central lymph nodes and tumors measuring > 1 cm in diameter than in patients with Hashimoto’s thyroiditis (Table 3).Table 3Comparison of numbers of central lymph nodes in each subgroup between the POI and the IOI groups in patients with different conditions.FactorsSubgroups of central lymph nodesPOI groupIOI group95% CIPHashimoto’s thyroiditisDelphian lymph nodes1 (0, 1)1 (0, 1)0.00–1.000.541Linea alba cervical lymph nodes1 (0, 1)0 (0, 1)0.00–1.000.012Pretracheal and paratracheal lymph nodes8.67 ± 1.987.70 ± 2.12 − 0.66–2.000.066cN1Delphian lymph nodes0 (0, 1)1 (0, 1)0.00–0.000.915Linea alba cervical lymph nodes1 (0, 1)0 (0, 0)0.00–0.000.020Pretracheal and paratracheal lymph nodes7.66 ± 1.816.70 ± 1.700.08–1.840.033Tumor diameter > 1 cmDelphian lymph nodes1 (0, 2)1 (0, 1)0.00–0.000.574Linea alba cervical lymph nodes0 (0, 1)0 (0, 0)0.00–0.000.005Pretracheal and paratracheal lymph nodes8.25 ± 2.387.21 ± 2.430.06–2.020.038Variables with normal distribution were presented with mean ± standard deviation \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\left( {\overline{x} \pm {\text{s}}} \right)$$\end{document}, and analyzed using independent samples t-test. Variables that did not conform to normal distribution were represented as M (P25, P75), and analyzed using Mann–Whitney U test. Table 3Comparison of numbers of central lymph nodes in each subgroup between the POI and the IOI groups in patients with different conditions.FactorsSubgroups of central lymph nodesPOI groupIOI group95% CIPHashimoto’s thyroiditisDelphian lymph nodes1 (0, 1)1 (0, 1)0.00–1.000.541Linea alba cervical lymph nodes1 (0, 1)0 (0, 1)0.00–1.000.012Pretracheal and paratracheal lymph nodes8.67 ± 1.987.70 ± 2.12 − 0.66–2.000.066cN1Delphian lymph nodes0 (0, 1)1 (0, 1)0.00–0.000.915Linea alba cervical lymph nodes1 (0, 1)0 (0, 0)0.00–0.000.020Pretracheal and paratracheal lymph nodes7.66 ± 1.816.70 ± 1.700.08–1.840.033Tumor diameter > 1 cmDelphian lymph nodes1 (0, 2)1 (0, 1)0.00–0.000.574Linea alba cervical lymph nodes0 (0, 1)0 (0, 0)0.00–0.000.005Pretracheal and paratracheal lymph nodes8.25 ± 2.387.21 ± 2.430.06–2.020.038Variables with normal distribution were presented with mean ± standard deviation \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\left( {\overline{x} \pm {\text{s}}} \right)$$\end{document}, and analyzed using independent samples t-test. Variables that did not conform to normal distribution were represented as M (P25, P75), and analyzed using Mann–Whitney U test. Comparison of numbers of central lymph nodes in each subgroup between the POI and the IOI groups in patients with different conditions. Variables with normal distribution were presented with mean ± standard deviation \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\left( {\overline{x} \pm {\text{s}}} \right)$$\end{document}, and analyzed using independent samples t-test. Variables that did not conform to normal distribution were represented as M (P25, P75), and analyzed using Mann–Whitney U test. Staining of central lymph nodes A total of 1471 and 1318 central lymph nodes were dissected in the POI group and the IOI group, of which 232 and 226 were metastatic, respectively. The staining rates of central lymph nodes and metastatic central lymph nodes were higher in the POI group than in the IOI group. The percentage of Delphian lymph nodes stained was not significantly different between the groups. All the linea alba cervical lymph nodes were dyed in the POI group but were undyed in the IOI group, which was a significant difference. Pretracheal and paratracheal lymph nodes were more prone to be dyed in the POI group (Table 4). In patients with Hashimoto’s thyroiditis, abnormal central lymph nodes, and tumors measuring > 1 cm in diameter, the staining rates of the pretracheal and paratracheal lymph nodes were higher in the POI group (Table 5).Table 4Comparison of staining rate of the central lymph nodes between the POI and the IOI groups.POI group (dyed/total) (%)IOI group (dyed/total)95% CIPTotal central lymph nodes89.786.4%1.58–12.440.007Metastatic central lymph nodes79.769.9%0.45–11.310.015Delphian lymph nodes90.187.6%–4.99–5.880.505Linea alba cervical lymph nodes100082.57–93.430.000Pretracheal and paratracheal lymph nodes89.286.2% − 0.53–10.330.027Table 5Comparison of staining rates of pretracheal and paratracheal lymph nodes between the POI group and the IOI groups in patients with different conditions.ConditionsPOI group (dyed/total) (%)IOI group (dyed/total) (%)95% CIPHashimoto’s thyroiditis74.164.9 − 0.29–10.570.023cN169.856.72.93–13.790.004Tumor diameter > 1 cm84.177.30.13–10.990.018 Table 4Comparison of staining rate of the central lymph nodes between the POI and the IOI groups.POI group (dyed/total) (%)IOI group (dyed/total)95% CIPTotal central lymph nodes89.786.4%1.58–12.440.007Metastatic central lymph nodes79.769.9%0.45–11.310.015Delphian lymph nodes90.187.6%–4.99–5.880.505Linea alba cervical lymph nodes100082.57–93.430.000Pretracheal and paratracheal lymph nodes89.286.2% − 0.53–10.330.027 Comparison of staining rate of the central lymph nodes between the POI and the IOI groups. Table 5Comparison of staining rates of pretracheal and paratracheal lymph nodes between the POI group and the IOI groups in patients with different conditions.ConditionsPOI group (dyed/total) (%)IOI group (dyed/total) (%)95% CIPHashimoto’s thyroiditis74.164.9 − 0.29–10.570.023cN169.856.72.93–13.790.004Tumor diameter > 1 cm84.177.30.13–10.990.018 Comparison of staining rates of pretracheal and paratracheal lymph nodes between the POI group and the IOI groups in patients with different conditions. Pathological and IHC examination All the metastatic lymph nodes were pathologically examined to detect nanocarbon. Many nanocarbon particles were observed within the dyed metastatic lymph nodes (Fig. 1a). Approximately 20.3% and 30.1% of the metastatic lymph nodes were not dyed in the POI group and the IOI group, respectively. Among the undyed metastatic lymph nodes in the IOI group, 17.6% had few nanocarbon particles, which could not be visually identified (Fig. 1b, arrowhead). In comparison, no nanocarbon particles were detected within the undyed metastatic lymph nodes in the POI group.Fig. 1Different amounts of nanocarbon particles were detected in dyed and undyed metastatic lymph nodes via electron microscopy (hematoxylin eosin stain, 100 magnification times). (a) Large amounts of nanocarbon particles were found within a dyed metastatic lymph node; (b) few nanocarbon particles were found within an undyed metastatic lymph node, which could not be identified visually (arrow). Different amounts of nanocarbon particles were detected in dyed and undyed metastatic lymph nodes via electron microscopy (hematoxylin eosin stain, 100 magnification times). (a) Large amounts of nanocarbon particles were found within a dyed metastatic lymph node; (b) few nanocarbon particles were found within an undyed metastatic lymph node, which could not be identified visually (arrow). The capillary lymphatic vessels in the thyroid gland were observed via IHC staining with D2-40. Compared with those in the normal thyroid gland (Fig. 2a, arrowhead), the capillary lymphatic vessels in the gland affected by Hashimoto’s thyroiditis were relatively dilated (Fig. 2b, arrowhead).Fig. 2Immunohistochemical staining with D2-40 in the thyroids of patients with Hashimoto’s thyroiditis and normal controls. The capillary lymphatic vessels were relatively dilated in the thyroids of patients with Hashimoto’s thyroiditis (b, arrow) compared with those in the normal controls (a, arrow). Immunohistochemical staining with D2-40 in the thyroids of patients with Hashimoto’s thyroiditis and normal controls. The capillary lymphatic vessels were relatively dilated in the thyroids of patients with Hashimoto’s thyroiditis (b, arrow) compared with those in the normal controls (a, arrow). Discussion PTC is prone to metastasize to the lymph nodes in the early stage. Approximately 20–90% of patients with PTC have central lymph node metastasis at the time of diagnosis9,10. However, approximately 42% of central cervical lymph node metastases are misdiagnosed11. Most cases of central cervical recurrence are caused by incomplete CLND and may inversely correlate with the number of central lymph nodes12. Therefore, comprehensive removal of central lymph nodes is important for reducing the risk of cervical recurrence of PTC. As a lymph node tracer, nanocarbon has been widely used in cervical lymph node dissection in patients with PTC6. With a diameter of 150 nm, nanocarbon particles can penetrate the gap between epithelial cells of lymphatic capillaries and then accumulate in the lymph nodes of the corresponding region, leading to black staining of the lymph nodes and facilitating the identification and dissection of cervical lymph nodes12. Previous studies have shown that an intraoperative injection of nanocarbon can effectively aid the detection of more lymph nodes in patients with papillary thyroid cancer, which may allow for more radical dissection13–15. Compared with these studies, our research has several advantages. For the first time, we divided central lymph nodes into subgroups: linea alba cervical lymph nodes, Delphian lymph nodes, and pretracheal and paratracheal lymph nodes and analyzed them. Furthermore, we performed pathological examinations of the thyroid gland and the unstained lymph nodes to ascertain the reason why some lymph nodes remained unstained. In addition, this novel application of nanocarbon could avoid unexpected staining in the surgical field. In our study, nanocarbon extravasation occurred in 33 patients in the IOI group and in 0 patients in the POI group. This may be due to the adequate drainage time of nanocarbon, followed by complete filling of the lymphatic capillaries in the POI group. A hematoma developed between the sternothyroid muscle and the thyroid gland in 5 patients in the POI group during the early stage of the trial. As a result, we examined the blood flow of the thyroid gland using Doppler ultrasound to ensure that we would not injure the blood vessels during subsequent procedures. In addition, the patients were advised to press the anterior cervical region firmly for 15 min after the injection. No hematoma has developed since then. The skin was dyed in 1 patient in the initial stage of the trial. We optimized our method by retaining 0.2 ml of air in the syringe and withdrawing the syringe slowly at negative pressure after the injection. No subsequent skin staining was observed. Delphian lymph nodes, as central lymph nodes, are usually located anterior to the cricothyroid membrane16. Studies have shown a significant association between metastasis to Delphian lymph nodes and metastasis to other central lymph nodes17,18. In our study, the detection rate of Delphian lymph nodes was 61.3% in the POI group and 57.2% in the IOI group, which is consistent with previous findings of 31–76%17–19. There was no significant difference between the two groups in terms of the detection rate or number of Delphian lymph nodes. This is possibly because Delphian lymph nodes are superficially located relatively close to the thyroid glands and thus can be adequately stained regardless of the short drainage time when nanocarbon is injected intraoperatively. Linea alba cervical lymph nodes are located beneath the conjugation line of the bilateral sternohyoideus and sternothyroid muscles. These lymph nodes are usually covered by fat tissues and are thus easily ignored during surgery. Because linea alba cervical lymph nodes are ignored during surgery, they could be a potential site of cervical recurrence. In our study, 10.2% of the linea alba cervical lymph nodes were metastatic. The detection rate and number of linea alba cervical lymph nodes were greater in the POI group than in the IOI group. Moreover, all the linea alba cervical lymph nodes were stained in the POI group but not in the IOI group. In the IOI group, the cervical linea alba had to be dissected to expose the thyroid before the injection of nanocarbon, and the lymphatic drainage of the linea alba cervical lymph nodes may have been compromised. In comparison, impaired lymphatic drainage can be avoided in the POI group, allowing the linea alba cervical lymph nodes to be stained. Pretracheal and paratracheal lymph nodes are located between the contralateral margin of the trachea and the medial margin of the ipsilateral cervical sheath, which is inferior to the hyoid bone and superior to the suprasternal notch20. Pretracheal and paratracheal lymph nodes, which account for most central lymph nodes, have been studied extensively. The average number of harvested pretracheal and paratracheal lymph nodes was 7.4–921–24. The total number of pretracheal and paratracheal lymph nodes ranged from 3 to 42. A higher yield of pretracheal and paratracheal lymph nodes is associated with a lower recurrence rate25. Thorough dissection of pretracheal and paratracheal lymph nodes depends on surgical competence and skill. In the past decade, nanocarbon has been proven efficient in thyroid surgeries, leading to more extensive lymph node dissection26–28. In our study, the number of pretracheal and paratracheal lymph nodes was greater in the POI group than in the IOI group. This may be due to the sufficient drainage time in the POI group, which was approximately 24 h. In addition, the tissues below the thyroid isthmus are usually removed during the initial stage of surgery, thus potentially damaging the main lymphatic vessels and resulting in inadequate staining of the pretracheal and paratracheal lymph nodes. Notably, Yan et al.8 reported that the number and staining rate of central lymph nodes were higher when nanocarbon was injected 1 month before surgery. For central lymph nodes, especially those with diameters < 5 mm, adequate drainage and staining are beneficial for their identification and dissection during surgery. Chronic lymphocytic thyroiditis, also known as Hashimoto’s thyroiditis, is characterized by lymphocyte infiltration, fibrosis, and parenchymal atrophy of thyroid tissues29. Studies have revealed a positive association between Hashimoto’s thyroiditis and papillary thyroid carcinoma30–32. In our study, 20.9% of the enrolled patients had coexistent Hashimoto’s thyroiditis, which is consistent with the findings of several previous studies32,33. Chen et al.34 reported that in patients with Hashimoto’s thyroiditis, central lymph nodes were prone to remain unstained when nanocarbon was injected intraoperatively34. They presumed that the development of fibrosis in patients with Hashimoto’s thyroiditis affected the diffusion of nanocarbon, leading to poor staining of the lymph nodes, which was consistent with our findings. IHC examination revealed that the capillary lymphatic vessels in the patients with Hashimoto’s thyroiditis were dilated, indicating that lymph drainage was relatively difficult. This may partly explain the mediocre staining of central lymph nodes in patients with Hashimoto’s thyroiditis. In the POI group, the degree of central lymph node staining improved owing to the sufficient draining time. The benefits of preoperatively injecting nanocarbon were also observed in cN1 patients. Previous studies revealed that conventional ultrasound missed 33–90% of central lymph node metastases, especially early metastases35–37. The metastatic features of central lymph nodes usually include node enlargement, loss of fatty hilum, a round rather than oval shape, hyperechogenicity, cystic changes, peripheral vascularity, and calcification38. Central lymph nodes with these suspicious signs are usually at an advanced metastatic stage, and the lymphatic hilum is more likely to be involved39. As reported by Yu et al.15 some central lymph nodes could not be stained with nanocarbon. They assumed that this may be due to the blockage of lymphatic flow and the interruption of lymphatic duct drainage15. In our study, 17.6% of the undyed metastatic lymph nodes detected in the IOI group exhibited a small amount of nanocarbon particles, which could not be identified visually. However, in the POI group, no nanocarbon particles were detected within the undyed metastatic lymph nodes. We speculated that when the lymphatic hilum of the metastatic lymph nodes was partly invaded by the tumor, lymphatic drainage was relatively difficult. This disadvantage can be circumvented by injecting nanocarbon preoperatively. However, for metastatic lymph nodes, in which the lymphatic hilum is completely invaded by the tumor, even an ample drainage time cannot ensure the adequate staining of central lymph nodes. As reported by Chen et al.34 a tumor diameter over > 1 cm was also one of the factors negatively affecting the staining of central lymph nodes with nanocarbon. In our study, the number and staining rate of pretracheal and paratracheal lymph nodes in patients with tumors over 1 cm in diameter increased when nanocarbon was injected preoperatively under ultrasound guidance. There may be two reasons for this. First, patients with tumors larger than 1 cm may have more impaired lymphatic drainage channels34. Second, larger tumors are more likely to be associated with central lymph node metastasis7,40,41, which can affect the degree of central lymph node staining. Our study has several limitations. For example, there was a small number of patients in the study, especially in each subgroup. In addition, we did not measure the diameter of each central lymph node; therefore, its effect on the detection rate could not be assessed. Furthermore, lateral cervical lymph nodes were neither stained nor detected. Thus, additional case studies involving the staining and detection of small and lateral lymph nodes are needed to confirm the advantages of injecting nanocarbon preoperatively. Conclusion Ultrasound-guided injection of nanocarbon is feasible for tracing central lymph nodes before surgery for PTC. This method can reduce intraoperative dye spillage and achieve more adequate staining of central lymph nodes. For patients with Hashimoto’s thyroiditis, abnormal central lymph nodes, or tumors measuring > 1 cm in diameter, preoperative ultrasound-guided injection of nanocarbon can increase the staining rate and detection rate of central lymph nodes. Methods Patient enrollment Between March 2023 and November 2023, 302 consecutive patients were recruited for this prospective study. The inclusion criteria were (1) a single focal tumor diagnosed as PTC via fine needle biopsy; (2) multifocal tumors within a unilateral lobe; and (3) planning to undergo ipsilateral central lymph node dissection. The exclusion criteria were as follows: (1) hyperthyroidism; (2) previous thyroidectomy or cervical lymph node dissection; (3) previous thyroid ablation; (4) isthmic tumors and planning to undergo bilateral central lymph node dissection; (5) a single focal tumor and suspicious bilateral central lymph nodes; and (6) refused to participate in clinical trials. The baseline characteristics of the enrolled patients were recorded in an Excel file. The rank function was used to generate a random number for each patient. The patients were subsequently divided into a preoperative ultrasound-guided injection (POI) group and an intraoperative injection (IOI) group according to the rank of the random numbers. Routine ultrasound examination of central lymph nodes All patients underwent routine ultrasound examination of the thyroid and central lymph nodes. Central lymph nodes were classified as cN1 if they presented with any metastatic features, including node enlargement, loss of fatty hilum, a round rather than oval shape, hyperechogenicity, cystic changes, peripheral vascularity, and calcification. Ultrasound-guided injection of nanocarbon Nanocarbon (LUMMY™, China) was injected 17–24 h before the operation by a surgeon with ten years of experience in fine needle aspiration of thyroid nodules. Before the procedure, 0.2 mL of nanocarbon suspension was extracted into a tuberculin syringe with a 22G needle. First, 0.2 mL of air was retained in the syringe to sweep away the residual nanocarbon in the needle (Fig. 3). The blood flow of the thyroid was assessed using color Doppler ultrasound to avoid hemorrhage. The puncture site was selected on the basis of a relatively short puncture path that avoided blood vessels. Under ultrasound guidance, the needle was placed into the thyroid gland adjacent to the tumor, then the nanocarbon solution was slowly injected; hyperechogenicity was observed on the ultrasound image. The needle was gently withdrawn with negative pressure. After the procedure, each patient pressed the anterior cervical region for 15 min.Fig. 3A 0.2 ml nanocarbon suspension was extracted into a tuberculin syringe with a 22G needle. Air (0.2 ml) was previously retained in the syringe. A 0.2 ml nanocarbon suspension was extracted into a tuberculin syringe with a 22G needle. Air (0.2 ml) was previously retained in the syringe. Intraoperative injection of a nanocarbon solution During the operation, when the thyroid was exposed, 0.2 mL of the nanocarbon suspension was injected into the thyroid gland adjacent to the tumor using a tuberculin syringe with a 25G needle. The thyroid was then massaged for 3 min to promote the infiltration of nanocarbon. Surgery All the surgeries were conducted by a skilled surgeon with 20 years of experience in thyroidectomy and cervical lymph node dissection. A lobectomy was performed if the patient was diagnosed with a single focal tumor localized in a unilateral lobe. Patients who were diagnosed with multifocal tumors as well as lateral cervical lymph node metastasis, and had a tumor measuring > 4 cm in diameter, or had gross extrathyroidal extension underwent total thyroidectomy. If fast frozen pathological examination revealed that the tumor was PTC, complete ipsilateral central lymph node dissection (CLND) was performed. In the POI group, black staining of the glands indicated that the preoperative injection was successful. The central lymph nodes are divided into 3 subgroups: linea alba cervical lymph nodes, prelaryngeal lymph nodes (also known as Delphian lymph nodes), and pretracheal and paratracheal lymph nodes. The numbers and staining status of central lymph nodes in each subgroup were recorded. All the lymph nodes were subsequently subjected to paraffin sectioning for further pathological examination. Immunohistochemical (IHC) staining IHC staining of the thyroid gland with D2-40 was performed to evaluate the lymphatic capillary vessels in the thyroid. Statistical analysis The Kolmogorov‒Smirnov (K–S) test was used to determine whether the data were normally distributed. Continuous variables with a normal distribution are presented as means ± standard deviations (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{x} \pm s$$\end{document}) and were analyzed using independent samples t tests. Continuous variables that did not conform to a normal distribution were represented as M (P25, P75) and were analyzed using the Mann–Whitney U test. Categorical data, including the proportion of each sex, staining rate, rate of nanocarbon extravasation, and detection rate of central lymph nodes, were analyzed using the chi-square test. SPSS 26.0 was used for statistical analysis. A P value < 0.05 indicated statistical significance.